The prescribed dosage for Breo Ellipta may depend on your individual treatment plan. Factors like your condition, medical history, age, and other treatments you take may affect your dosage of Breo ...
Breo Ellipta is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) in adults and asthma in adults and children ages 5 years and older. Breo Ellipta comes as a powder that ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, a ...
DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to BREO ELLIPTA ...
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO ® ELLIPTA ® (fluticasone furoate/vilanterol [FF/VI]) ...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily ...
MISSISSAUGA, ON, July 10, 2013 /CNW/ - BREO™ ELLIPTA™ (fluticasone furoate/vilanterol) has been approved in Canada for the long-term once-daily maintenance treatment of airflow obstruction in patients ...
RESEARCH TRIANGLE PARK, NC and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 30, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results